NexoBrid, a burn debridement product used to treat victims of incidents involving improvised nuclear devices, was the subject of a case study led by the University of Maryland School of Public Health’s Dr. Farah Farahati. Her team looked at the potential economic spillover that would result in NexoBrid being used in the day-to-day health care system to improve burn patient outcomes and reduce hospital stays.
[Photo: Dr. Farah Farahati]
According to the publication, the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) awarded a $24 million contract to MediWound Ltd. for the development of NexoBrid. “If approved in the U.S., the burn debridement product would be available for use in routine burn care beyond its primary mission. BARDA’s investment as potential economic spillover benefits that exceed BARDA’s initial investment of $24 million a few years after its entrance into the U.S. market.”
The team led by Dr. Farahati, a population health economist with the UMD Department of Health Services Administration, concluded that “Because multi-functionality of a medical counter-measure is a key consideration of the Public Health Emergency Medical Countermeasure Enterprise (PHEMCE) when making resource decisions, the results of this analysis can help to inform prioritization of scarce resources for development by the PHEMCE. Future Federal investment decisions could incorporate consideration of potential economic spillover benefits when a product could be used routinely in the commercial market.”
“Economic Spillovers from Public Medical Countermeasure Investments: A Case Study of NexoBrid” was published in the Annals of Global Health: http://www.annalsofglobalhealth.org/article/S2214-9996(17)30093-0/abstractTags: Health Policy and Management, Maryland, Preparedness